Raras
Buscar doenças, sintomas, genes...
Doença congênita da glicosilação
ORPHA:137CID-10 · E77.8DOENÇA RARA

As Doenças Congênitas da Glicosilação (CDG) formam um grupo de erros inatos do metabolismo que está sendo cada vez mais reconhecido. Elas são caracterizadas por um problema na atividade das enzimas que participam da glicosilação – um processo em que proteínas e outras moléculas grandes são modificadas pela adição e alteração de pequenas cadeias de açúcar. Essas doenças abrangem uma grande variedade de manifestações e afetam diversas partes do corpo, como o sistema nervoso central, a função dos músculos, o sistema imunológico, o sistema endócrino e a coagulação (formação de coágulos). As muitas doenças que fazem parte desse grupo são subdivididas, de acordo com o tipo específico de processo de glicosilação que é afetado. As categorias incluem: problemas na N-glicosilação de proteínas, problemas na O-glicosilação de proteínas, problemas em múltiplos tipos de glicosilação e problemas na glicosilação de glicosfingolipídios e âncoras de glicosilfosfatidilinositol.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

As Doenças Congênitas da Glicosilação (CDG) formam um grupo de erros inatos do metabolismo que está sendo cada vez mais reconhecido. Elas são caracterizadas por um problema na atividade das enzimas que participam da glicosilação – um processo em que proteínas e outras moléculas grandes são modificadas pela adição e alteração de pequenas cadeias de açúcar. Essas doenças abrangem uma grande variedade de manifestações e afetam diversas partes do corpo, como o sistema nervoso central, a função dos músculos, o sistema imunológico, o sistema endócrino e a coagulação (formação de coágulos). As muitas doenças que fazem parte desse grupo são subdivididas, de acordo com o tipo específico de processo de glicosilação que é afetado. As categorias incluem: problemas na N-glicosilação de proteínas, problemas na O-glicosilação de proteínas, problemas em múltiplos tipos de glicosilação e problemas na glicosilação de glicosfingolipídios e âncoras de glicosilfosfatidilinositol.

Pesquisas ativas
5 ensaios
20 total registrados no ClinicalTrials.gov
Publicações científicas
727 artigos
Último publicado: 2026 Apr 16
Medicamentos
2 registrados
EPALRESTAT, ACETAZOLAMIDE

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
EPALRESTATACETAZOLAMIDE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Infancy
+ neonatal
🏥
SUS: Cobertura mínimaScore: 35%
Centros em: PA, PR, SC, RS, ES +10CID-10: E77.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (6)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
197 sintomas
🧠
Neurológico
152 sintomas
💪
Músculos
85 sintomas
😀
Face
78 sintomas
🫃
Digestivo
73 sintomas
🧬
Pele e cabelo
67 sintomas

+ 680 sintomas em outras categorias

Características mais comuns

Vacúolos com bordas
Anormalidade da fisiologia do sistema imunológico
Anormalidades de segmentação costal
Morfologia anormal do disco intervertebral
Desvio tibial do segundo dedo do pé
Incisivos espaçados anormais
1686sintomas
Sem dados (1686)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 1686 características clínicas mais associadas, ordenadas por frequência.

Vacúolos com bordasRimmed vacuoles
Anormalidade da fisiologia do sistema imunológicoAbnormality of immune system physiology
Anormalidades de segmentação costalRib segmentation abnormalities
Morfologia anormal do disco intervertebralAbnormal intervertebral disk morphology
Desvio tibial do segundo dedo do péTibial deviation of the 2nd toe

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico727PubMed
Últimos 10 anos200publicações
Pico202565 papers
Linha do tempo
2026Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

69 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive, X-linked recessive.

PGM1Phosphoglucomutase-1Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible isomerization of alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate (PubMed:15378030, PubMed:25288802). The mechanism proceeds via the intermediate compound alpha-D-glucose 1,6-bisphosphate (Probable) (PubMed:25288802). This enzyme participates in both the breakdown and synthesis of glucose (PubMed:17924679, PubMed:25288802)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (3)
Galactose catabolismGlycogen breakdown (glycogenolysis)Glycogen synthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1T

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
426.4 TPM
Coração - Ventrículo esquerdo
83.4 TPM
Aorta
80.8 TPM
Fígado
77.2 TPM
Coração - Átrio
72.0 TPM
OUTRAS DOENÇAS (1)
PGM1-congenital disorder of glycosylation
HGNC:8905UniProt:P36871
FCSKL-fucose kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Takes part in the salvage pathway for reutilization of fucose from the degradation of oligosaccharides

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
GDP-fucose biosynthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation with defective fucosylation 2

A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. CDGF2 is an autosomal recessive disorder, apparent from birth, characterized by hypotonia, poor feeding, severely impaired intellectual and psychomotor development, seizures with epileptic encephalopathy, visual impairment and other ocular features, respiratory difficulty with frequent infections, as well as contractures. Brain imaging shows cerebellar and brainstem atrophy, hypoplasia or agenesis of the corpus callosum, and white matter abnormalities including periventricular leukomalacia.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation with defective fucosylation 2
HGNC:HGNC:29500UniProt:Q8N0W3
DHRSXPolyprenol dehydrogenaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Oxidoreductase that plays a key role in early steps of protein N-linked glycosylation by mediating two non-consecutive steps in dolichol biosynthesis (PubMed:38821050). Acts both as a NAD(+)-dependent dehydrogenase and as a NADPH-dependent reductase during the conversion of polyprenol into dolichol (PubMed:38821050). First catalyzes the NAD(+)-dependent dehydrogenation of polyprenol into polyprenal; polyprenal is then reduced into dolichal by SRD5A3 (PubMed:38821050). It then catalyzes the NADPH

LOCALIZAÇÃO

Lipid dropletSecreted

VIAS BIOLÓGICAS (1)
Synthesis of dolichyl-phosphate
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1DD

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1DD transmission pattern is consistent with pseudoautosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
18.7 TPM
Fibroblastos
18.5 TPM
Cervix Ectocervix
16.0 TPM
Tireoide
15.7 TPM
Próstata
14.9 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation, type 1DD
HGNC:HGNC:18399UniProt:Q8N5I4
FUT8Alpha-(1,6)-fucosyltransferaseDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalyzes the addition of fucose in alpha 1-6 linkage to the first GlcNAc residue, next to the peptide chains in N-glycans (PubMed:17172260, PubMed:29304374, PubMed:36280670, PubMed:9133635). Fucosylates the reducing GlcNAc residue in complex-type N-glycans attached on the fragment crystallizable (Fc) of IgGs. Fully converts Fc glycoforms containing one or two terminal GlcNAc moieties (G0-GlcNAc and G0) (PubMed:36280670)

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membrane

VIAS BIOLÓGICAS (2)
Maturation of spike proteinReactions specific to the complex N-glycan synthesis pathway
MECANISMO DE DOENÇA

Congenital disorder of glycosylation with defective fucosylation 1

A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDGF1 is an autosomal recessive disorder, apparent from birth, characterized by poor growth, failure to thrive, hypotonia, skeletal anomalies, and delayed psychomotor development with intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
32.6 TPM
Nervo tibial
32.0 TPM
Brain Spinal cord cervical c-1
31.6 TPM
Fibroblastos
25.5 TPM
Cérebro - Hemisfério cerebelar
19.5 TPM
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation with defective fucosylation 1
HGNC:HGNC:4019UniProt:Q9BYC5
MPDU1Mannose-P-dolichol utilization defect 1 proteinCandidate gene tested inTolerante
FUNÇÃO

Required for normal utilization of mannose-dolichol phosphate (Dol-P-Man) in the synthesis of N-linked and O-linked oligosaccharides and GPI anchors

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1F

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
64.0 TPM
Rim - Medula
52.5 TPM
Glândula adrenal
51.2 TPM
Tireoide
49.1 TPM
Baço
47.6 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
MPDU1-congenital disorder of glycosylation
HGNC:7207UniProt:O75352
EXT2Exostosin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Glycosyltransferase forming with EXT1 the heterodimeric heparan sulfate polymerase which catalyzes the elongation of the heparan sulfate glycan backbone (PubMed:22660413, PubMed:36402845, PubMed:36593275). Glycan backbone extension consists in the alternating transfer of (1->4)-beta-D-GlcA and (1->4)-alpha-D-GlcNAc residues from their respective UDP-sugar donors. Both EXT1 and EXT2 are required for the full activity of the polymerase since EXT1 bears the N-acetylglucosaminyl-proteoglycan 4-beta-

LOCALIZAÇÃO

Golgi apparatus membraneGolgi apparatus, cis-Golgi network membraneEndoplasmic reticulum membraneSecreted

VIAS BIOLÓGICAS (2)
HS-GAG biosynthesisDefective EXT1 causes exostoses 1, TRPS2 and CHDS
MECANISMO DE DOENÇA

Hereditary multiple exostoses 2

EXT is a genetically heterogeneous bone disorder caused by genes segregating on human chromosomes 8, 11, and 19 and designated EXT1, EXT2 and EXT3 respectively. EXT is a dominantly inherited skeletal disorder primarily affecting endochondral bone during growth. The disease is characterized by formation of numerous cartilage-capped, benign bone tumors (osteocartilaginous exostoses or osteochondromas) that are often accompanied by skeletal deformities and short stature. In a small percentage of cases exostoses have exhibited malignant transformation resulting in an osteosarcoma or chondrosarcoma. Osteochondromas development can also occur as a sporadic event.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
101.7 TPM
Útero
68.9 TPM
Cervix Endocervix
62.0 TPM
Aorta
59.6 TPM
Cervix Ectocervix
58.9 TPM
OUTRAS DOENÇAS (4)
seizures-scoliosis-macrocephaly syndromeexostoses, multiple, type 2Potocki-Shaffer syndromehereditary multiple osteochondromas
HGNC:3513UniProt:Q93063
ALG3Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1D

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG3-congenital disorder of glycosylation
HGNC:23056UniProt:Q92685
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
ALG11GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two G

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1P

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG11-congenital disorder of glycosylation
HGNC:32456UniProt:Q2TAA5
VMA22Vacuolar ATPase assembly protein VMA22Candidate gene tested inTolerante
FUNÇÃO

Accessory component of the proton-transporting vacuolar (V)-ATPase protein pump involved in intracellular iron homeostasis. In aerobic conditions, required for intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation. Necessary for endolysosomal acidification and lysosomal degradation (PubMed:28296633). May be involved in Golgi homeostasis (PubMed:26833332)

LOCALIZAÇÃO

EndosomeLysosomeEndoplasmic reticulum-Golgi intermediate compartmentCytoplasmic vesicle, COPI-coated vesicleEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
RHOA GTPase cycle
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2O

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2O is characterized by hepatosplenomegaly, liver failure, hypotonia, and psychomotor disability.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
CCDC115-CDG
HGNC:28178UniProt:Q96NT0
GNEBifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme that possesses both UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities, and serves as the initiator of the biosynthetic pathway leading to the production of N-acetylneuraminic acid (NeuAc), a critical precursor in the synthesis of sialic acids. By catalyzing this pivotal and rate-limiting step in sialic acid biosynthesis, this enzyme assumes a pivotal role in governing the regulation of cell surface sialylation, playing a role in embryonic angiogene

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Sialic acid metabolism
MECANISMO DE DOENÇA

Sialuria

In sialuria, free sialic acid accumulates in the cytoplasm and gram quantities of neuraminic acid are secreted in the urine. The metabolic defect involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, resulting in constitutive overproduction of free Neu5Ac. Clinical features include variable degrees of developmental delay, coarse facial features and hepatomegaly. Sialuria inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
33.4 TPM
Glândula salivar
24.0 TPM
Cérebro - Hemisfério cerebelar
23.1 TPM
Cólon transverso
21.3 TPM
Ovário
21.0 TPM
OUTRAS DOENÇAS (4)
GNE myopathysialuriathrombocytopenia 12 with or without myopathyplatelet-type bleeding disorder 19
HGNC:23657UniProt:Q9Y223
B3GALT6Beta-1,3-galactosyltransferase 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,3-galactosyltransferase that transfers galactose from UDP-galactose to substrates with a terminal beta-linked galactose residue. Has a preference for galactose-beta-1,4-xylose that is found in the linker region of glycosaminoglycans, such as heparan sulfate and chondroitin sulfate. Has no activity towards substrates with terminal glucosamine or galactosamine residues

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membrane

VIAS BIOLÓGICAS (1)
Glycosaminoglycan-protein linkage region biosynthesis
MECANISMO DE DOENÇA

Ehlers-Danlos syndrome, spondylodysplastic type, 2

A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSSPD2 is an autosomal recessive form characterized by an aged appearance, developmental delay, short stature, craniofacial disproportion, generalized osteopenia, defective wound healing, hypermobile joints, hypotonic muscles, and loose but elastic skin.

OUTRAS DOENÇAS (3)
spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fracturesEhlers-Danlos syndrome, spondylodysplastic type, 2Al-Gazali syndrome
HGNC:17978UniProt:Q96L58
ALG12Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1G

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG12-congenital disorder of glycosylation
HGNC:19358UniProt:Q9BV10
B4GALT1Beta-1,4-galactosyltransferase 1Candidate gene tested inTolerante
FUNÇÃO

Galactosyltransferase acting in the Golgi stacks. Catalyzes the transfer of galactose (Gal) from UDP-alpha-D-galactose in beta(1->4) linkage to the non-reducing terminal N-acetylglucosamine (GlcNAc) moieties of glycolipids and complex-type N-linked glycans (PubMed:16157350, PubMed:27872474, PubMed:29133956, PubMed:36280670, PubMed:37632720, PubMed:38321209). Adds one Gal residue to both GlcNAc beta(1->2)-linked to the alpha(1->3) and alpha(1->6) mannose antennae of complex-type N-glycans, enabli

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membraneCell membraneCell surfaceCell projection, filopodiumSecreted

VIAS BIOLÓGICAS (4)
Pre-NOTCH Processing in GolgiKeratan sulfate biosynthesisN-Glycan antennae elongationLactose synthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2D

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
combined low LDL and fibrinogenB4GALT1-congenital disorder of glycosylation
HGNC:924UniProt:P15291
POGLUT1Protein O-glucosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Dual specificity glycosyltransferase that catalyzes the transfer of glucose and xylose from UDP-glucose and UDP-xylose, respectively, to a serine residue found in the consensus sequence of C-X-S-X-P-C (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Specifically targets extracellular EGF repeats of protein such as CRB2, F7, F9 and NOTCH2 (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Acts as a positive regulator of Not

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
Pre-NOTCH Processing in the Endoplasmic Reticulum
MECANISMO DE DOENÇA

Dowling-Degos disease 4

A form of Dowling-Degos disease, a genodermatosis manifesting with postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. DDD4 is characterized by prominent involvement of non-flexural skin areas.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
18.8 TPM
Linfócitos
18.3 TPM
Cervix Ectocervix
17.1 TPM
Cervix Endocervix
16.6 TPM
Baço
16.2 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2R1Dowling-Degos disease 4Dowling-Degos disease
HGNC:22954UniProt:Q8NBL1
COG1Conserved oligomeric Golgi complex subunit 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2G

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2G include failure to thrive, generalized hypotonia, growth retardation and mild psychomotor retardation. CDG2G is biochemically characterized by a defect in O-glycosylation as well as N-glycosylation.

OUTRAS DOENÇAS (1)
COG1-congenital disorder of glycosylation
HGNC:6545UniProt:Q8WTW3
COG4Conserved oligomeric Golgi complex subunit 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function (PubMed:19536132, PubMed:30290151). Plays a role in SNARE-pin assembly and Golgi-to-ER retrograde transport via its interaction with SCFD1 (PubMed:19536132)

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2J

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
microcephalic osteodysplastic dysplasia, Saul-Wilson typeCOG4-congenital disorder of glycosylation
HGNC:18620UniProt:Q9H9E3
MPIMannose-6-phosphate isomeraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Isomerase that catalyzes the interconversion of fructose-6-P and mannose-6-P and has a critical role in the supply of D-mannose derivatives required for many eukaryotic glycosylation reactions

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1B

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1B is clinically characterized by protein-losing enteropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
31.8 TPM
Glândula adrenal
25.9 TPM
Ovário
23.0 TPM
Fibroblastos
23.0 TPM
Testículo
21.5 TPM
OUTRAS DOENÇAS (1)
MPI-congenital disorder of glycosylation
HGNC:7216UniProt:P34949
ALG2Programmed cell death protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium sensor that plays a key role in processes such as endoplasmic reticulum (ER)-Golgi vesicular transport, endosomal biogenesis or membrane repair. Acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium: calcium-binding triggers exposure of apolar surface, promoting interaction with different sets of proteins thanks to 3 different hydrophobic pockets, leading to translocation to membranes (PubMed:20691033, PubMed:25667979). Inv

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, COPII-coated vesicle membraneCytoplasmNucleusEndosome

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 14ALG2-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:23159UniProt:O75340
DPAGT1UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseCandidate gene tested inTolerante
FUNÇÃO

UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen su

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1J

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
50.3 TPM
Cervix Endocervix
43.7 TPM
Útero
39.0 TPM
Fallopian Tube
38.1 TPM
Próstata
37.8 TPM
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 13DPAGT1-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:2995UniProt:Q9H3H5
EDEM3ER degradation-enhancing alpha-mannosidase-like protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in endoplasmic reticulum-associated degradation (ERAD). Accelerates the glycoprotein ERAD by proteasomes, by catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans (PubMed:25092655). May also participate in mannose trimming from all glycoproteins and not just misfolded ones targeted to ERAD (PubMed:34143952). May have alpha 1,2-mannosidase activity (By similarity)

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
ER Quality Control Compartment (ERQC)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2V

A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2V is an autosomal recessive form characterized by neurodevelopmental delay and variable facial dysmorphic features.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
36.6 TPM
Pituitária
23.1 TPM
Cervix Ectocervix
22.9 TPM
Artéria coronária
22.9 TPM
Aorta
22.4 TPM
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation, type 2v
HGNC:16787UniProt:Q9BZQ6
PIGTGPI-anchor transamidase component PIGTDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase (GPI-T) complex that catalyzes the formation of the linkage between a proprotein and a GPI-anchor and participates in GPI anchored protein biosynthesis (PubMed:11483512, PubMed:12582175, PubMed:28327575, PubMed:34576938, PubMed:35165458, PubMed:35551457, PubMed:36970549, PubMed:37684232). May play a crucial role in GPI-T complex assembly in the luminal layer (PubMed:35165458, PubMed:35551457). Binds GPI-anchor (PubMed

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Attachment of GPI anchor to uPAR
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 3

An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
53.6 TPM
Artéria coronária
42.9 TPM
Artéria tibial
38.8 TPM
Útero
35.9 TPM
Fibroblastos
35.5 TPM
OUTRAS DOENÇAS (2)
multiple congenital anomalies-hypotonia-seizures syndrome 3paroxysmal nocturnal hemoglobinuria 2
HGNC:14938UniProt:Q969N2
MOGSMannosyl-oligosaccharide glucosidaseCandidate gene tested inTolerante
FUNÇÃO

In the context of N-glycan degradation, cleaves the distal alpha 1,2-linked glucose residue from the Glc(3)Man(9)GlcNAc(2) oligosaccharide precursor in a highly specific manner

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Maturation of spike proteinMaturation of spike proteinRegulation of CDH1 posttranslational processing and trafficking to plasma membraneN-glycan trimming in the ER and Calnexin/Calreticulin cycle
MECANISMO DE DOENÇA

Type IIb congenital disorder of glycosylation

Characterized by marked generalized hypotonia and hypomotility of the neonate, dysmorphic features, including a prominent occiput, short palpebral fissures, retrognathia, high arched palate, generalized edema, and hypoplastic genitalia. Symptoms of the infant included hepatomegaly, hypoventilation, feeding problems and seizures. The clinical course was progressive and the infant did not survive more than a few months.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.2 TPM
Baço
83.4 TPM
Pituitária
75.9 TPM
Fibroblastos
75.1 TPM
Próstata
74.9 TPM
OUTRAS DOENÇAS (1)
MOGS-congenital disorder of glycosylation
HGNC:24862UniProt:Q13724
PIGYPhosphatidylinositol N-acetylglucosaminyltransferase subunit YDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:16162815). May act by regulating the catalytic subunit PIGA (PubMed:16162815)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 6

An autosomal recessive, multisystem disorder characterized by severe developmental delay, dysmorphism, seizures, cataracts, and early death in some patients.

OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 6hyperphosphatasia-intellectual disability syndrome
HGNC:28213UniProt:Q3MUY2
ALG1Chitobiosyldiphosphodolichol beta-mannosyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1K

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG1-congenital disorder of glycosylation
HGNC:18294UniProt:Q9BT22
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinCandidate gene tested inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777
SRD5A3Polyprenal reductaseCandidate gene tested inTolerante
FUNÇÃO

Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol (PubMed:20637498, PubMed:38821050). Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism (PubMed:38821050). Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation (PubMed:20637498, PubMed:38821050). Also able to convert testos

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Synthesis of dolichyl-phosphateAndrogen biosynthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1Q

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
14.3 TPM
Brain Spinal cord cervical c-1
12.7 TPM
Esôfago - Mucosa
12.4 TPM
Tecido adiposo
9.5 TPM
Vagina
9.2 TPM
OUTRAS DOENÇAS (2)
Kahrizi syndromeSRD5A3-congenital disorder of glycosylation
HGNC:25812UniProt:Q9H8P0
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
B3GLCTBeta-1,3-glucosyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Beta-1,3-glucosyltransferase involved in one of the two pathways responsible for protein O-linked fucosylation, a unique post-translational modification of cysteine-knotted proteins that regulates various biological processes. This pathway targets proteins with Thrombospondin type-1 (TSP1) repeats (TSR) in the endoplasmic reticulum. It starts with POFUT2, which attaches fucose via an O-glycosidic bond to a conserved serine or threonine residue. B3GLCT extends this modification by transferring a

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
O-glycosylation of TSR domain-containing proteins
MECANISMO DE DOENÇA

Peters-plus syndrome

An autosomal recessive disorder characterized by anterior eye-chamber abnormalities, disproportionate short stature, developmental delay, characteristic craniofacial features, cleft lip and/or palate.

OUTRAS DOENÇAS (1)
Peters plus syndrome
HGNC:20207UniProt:Q6Y288
MGAT2Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
Maturation of spike proteinReactions specific to the complex N-glycan synthesis pathway
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2A

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
35.6 TPM
Linfócitos
34.8 TPM
Testículo
21.6 TPM
Cervix Ectocervix
11.6 TPM
Baço
11.4 TPM
OUTRAS DOENÇAS (1)
MGAT2-congenital disorder of glycosylation
HGNC:7045UniProt:Q10469
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
MESP2Mesoderm posterior protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor with important role in somitogenesis. Defines the rostrocaudal patterning of the somite by participating in distinct Notch pathways. Also regulates the FGF signaling pathway. Specifies the rostral half of the somites. Generates rostro-caudal polarity of somites by down-regulating in the presumptive rostral domain DLL1, a Notch ligand. Participates in the segment border formation by activating in the anterior presomitic mesoderm LFNG, a negative regulator of DLL1-Notch signal

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Somitogenesis
MECANISMO DE DOENÇA

Spondylocostal dysostosis 2, autosomal recessive

A condition of variable severity associated with vertebral and rib segmentation defects. The main skeletal malformations include fusion of vertebrae, hemivertebrae, fusion of certain ribs, and other rib malformations. Deformity of the chest and spine (severe scoliosis, kyphoscoliosis and lordosis) is a natural consequence of the malformation and leads to a dwarf-like appearance. As the thorax is small, infants frequently have respiratory insufficiency and repeated respiratory infections resulting in life-threatening complications in the first year of life.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.6 TPM
Brain Frontal Cortex BA9
1.0 TPM
Córtex cerebral
0.9 TPM
Brain Nucleus accumbens basal ganglia
0.9 TPM
Glândula salivar
0.8 TPM
OUTRAS DOENÇAS (2)
spondylocostal dysostosis 2, autosomal recessiveautosomal recessive spondylocostal dysostosis
HGNC:29659UniProt:Q0VG99
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
ALG14UDP-N-acetylglucosamine transferase subunit ALG14Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the UDP-N-acetylglucosamine transferase complex that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAc

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 15

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness.

OUTRAS DOENÇAS (4)
intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse faciesmyopathy, epilepsy, and progressive cerebral atrophycongenital myasthenic syndrome 15obsolete congenital myasthenic syndromes with glycosylation defect
HGNC:28287UniProt:Q96F25
FKRPRibitol 5-phosphate transferase FKRPDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842, PubMed:31949166). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which links the phos

LOCALIZAÇÃO

Golgi apparatus membraneSecretedCell membrane, sarcolemmaRough endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A5

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
19.7 TPM
Útero
18.0 TPM
Fibroblastos
17.7 TPM
Tireoide
16.6 TPM
Fallopian Tube
16.5 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5muscular dystrophy-dystroglycanopathy type B5autosomal recessive limb-girdle muscular dystrophy type 2Imuscle-eye-brain disease
HGNC:17997UniProt:Q9H9S5
PIGLN-acetylglucosaminyl-phosphatidylinositol de-N-acetylaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the second step of glycosylphosphatidylinositol (GPI) biosynthesis, which is the de-N-acetylation of N-acetylglucosaminyl-phosphatidylinositol

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Coloboma, congenital heart disease, ichthyosiform dermatosis, impaired intellectual development, and ear anomalies syndrome

An extremely rare autosomal recessive multisystem disorder clinically characterized by colobomas, congenital heart defects, migratory ichthyosiform dermatosis, intellectual disability, and ear anomalies including conductive hearing loss. Other clinical features include distinctive facial features, abnormal growth, genitourinary abnormalities, seizures, and feeding difficulties.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
16.6 TPM
Skin Sun Exposed Lower leg
14.9 TPM
Nervo tibial
14.8 TPM
Tireoide
14.1 TPM
Mama
13.1 TPM
OUTRAS DOENÇAS (2)
CHIME syndromehyperphosphatasia-intellectual disability syndrome
HGNC:8966UniProt:Q9Y2B2
COG5Conserved oligomeric Golgi complex subunit 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2I

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Congenital disorder of glycosylation type 2I is characterized by mild neurological impairments.

OUTRAS DOENÇAS (1)
COG5-congenital disorder of glycosylation
HGNC:14857UniProt:Q9UP83
CADDNA fragmentation factor subunit betaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Pyrimidine biosynthesis
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 50
HGNC:1424UniProt:O76075
DPM1Dolichol-phosphate mannosyltransferase subunit 1Candidate gene tested inTolerante
FUNÇÃO

Transfers mannose from GDP-mannose to dolichol monophosphate to form dolichol phosphate mannose (Dol-P-Man) which is the mannosyl donor in pathways leading to N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins; catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1E

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
94.4 TPM
Fibroblastos
90.2 TPM
Testículo
78.2 TPM
Útero
70.8 TPM
Cervix Ectocervix
68.1 TPM
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation type 1E
HGNC:3005UniProt:O60762
PMM2Phosphomannomutase 2Candidate gene tested inTolerante
FUNÇÃO

Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1A

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1A is an autosomal recessive disorder characterized by a severe encephalopathy with axial hypotonia, abnormal eye movement, and pronounced psychomotor retardation, as well as peripheral neuropathy, cerebellar hypoplasia, and retinitis pigmentosa. Patients show a peculiar distribution of subcutaneous fat, nipple retraction, and hypogonadism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
31.1 TPM
Linfócitos
27.3 TPM
Esôfago - Mucosa
15.7 TPM
Glândula salivar
15.1 TPM
Cólon transverso
11.8 TPM
OUTRAS DOENÇAS (1)
PMM2-congenital disorder of glycosylation
HGNC:9115UniProt:O15305
MAN1B1Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidaseCandidate gene tested inTolerante
FUNÇÃO

Involved in glycoprotein quality control targeting of misfolded glycoproteins for degradation. It primarily trims a single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2), but at high enzyme concentrations, as found in the ER quality control compartment (ERQC), it further trims the carbohydrates to Man(5-6)GlcNAc(2)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Maturation of spike proteinER Quality Control Compartment (ERQC)
MECANISMO DE DOENÇA

Rafiq syndrome

An autosomal recessive disorder characterized by variably impaired intellectual and motor development, a characteristic facial dysmorphism, truncal obesity, and hypotonia. The facial dysmorphism comprises prominent eyebrows with lateral thinning, downward-slanting palpebral fissures, bulbous tip of the nose, large ears, and a thin upper lip. Behavioral problems, including overeating, verbal and physical aggression, have been reported in some cases. Serum transferrin isoelectric focusing shows a type 2 pattern.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
63.3 TPM
Nervo tibial
51.8 TPM
Pituitária
49.8 TPM
Testículo
49.4 TPM
Cérebro - Hemisfério cerebelar
47.3 TPM
OUTRAS DOENÇAS (3)
Rafiq syndromeMAN1B1-congenital disorder of glycosylationautosomal recessive non-syndromic intellectual disability
HGNC:6823UniProt:Q9UKM7
PSENENGamma-secretase subunit PEN-2Candidate gene tested inRestrito
FUNÇÃO

Essential subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein) (PubMed:12522139, PubMed:12679784, PubMed:12740439, PubMed:12763021, PubMed:24941111, PubMed:30598546, PubMed:30630874). The gamma-secretase complex plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins,

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus, Golgi stack membraneCell membraneMembrane

VIAS BIOLÓGICAS (10)
Activated NOTCH1 Transmits Signal to the NucleusNOTCH3 Activation and Transmission of Signal to the NucleusNOTCH4 Activation and Transmission of Signal to the NucleusNoncanonical activation of NOTCH3NOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Acne inversa, familial, 2, with or without Dowling-Degos disease

An autosomal dominant form of acne inversa, a chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty. Some ACNINV2 patients also exhibit reticulate hyperpigmentation consistent with Dowling-Degos disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
189.4 TPM
Tireoide
64.5 TPM
Cervix Endocervix
59.0 TPM
Pituitária
56.5 TPM
Sangue
55.5 TPM
OUTRAS DOENÇAS (2)
acne inversa, familial, 2Dowling-Degos disease
HGNC:30100UniProt:Q9NZ42
TBX6T-box transcription factor TBX6Candidate gene tested inTolerante
FUNÇÃO

T-box transcription factor that plays an essential role in the determination of the fate of axial stem cells: neural vs mesodermal. Acts in part by down-regulating, a specific enhancer (N1) of SOX2, to inhibit neural development. Seems to play also an essential role in left/right axis determination and acts through effects on Notch signaling around the node as well as through an effect on the morphology and motility of the nodal cilia (By similarity)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
Formation of paraxial mesodermSomitogenesisFormation of the posterior neural plate
MECANISMO DE DOENÇA

Spondylocostal dysostosis 5

A rare condition of variable severity characterized by vertebral and costal anomalies. The main feature include dwarfism, vertebral fusion, hemivertebrae, posterior rib fusion, reduced rib number, and other rib malformations. SCDO5 inheritance can be autosomal dominant or recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
10.7 TPM
Vagina
7.6 TPM
Bladder
4.0 TPM
Tireoide
3.8 TPM
Skin Not Sun Exposed Suprapubic
3.4 TPM
OUTRAS DOENÇAS (3)
spondylocostal dysostosis 5autosomal recessive spondylocostal dysostosisautosomal dominant spondylocostal dysostosis
HGNC:11605UniProt:O95947
HES7Transcription factor HES-7Candidate gene tested inModerado
FUNÇÃO

Transcriptional repressor. Represses transcription from both N box- and E box-containing promoters. May with HES1, cooperatively regulate somite formation in the presomitic mesoderm (PSM). May function as a segmentation clock, which is essential for coordinated somite segmentation (By similarity)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Somitogenesis
MECANISMO DE DOENÇA

Spondylocostal dysostosis 4, autosomal recessive

A rare condition of variable severity characterized by vertebral and costal anomalies. The main feature include dwarfism, vertebral fusion, hemivertebrae, posterior rib fusion, reduced rib number, and other rib malformations.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
7.0 TPM
Cérebro - Hemisfério cerebelar
5.8 TPM
Linfócitos
3.0 TPM
Nervo tibial
2.0 TPM
Córtex cerebral
1.5 TPM
OUTRAS DOENÇAS (2)
spondylocostal dysostosis 4, autosomal recessiveautosomal recessive spondylocostal dysostosis
HGNC:15977UniProt:Q9BYE0
PGAP3GPI-specific phospholipase A2-like PGAP3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the fatty acid remodeling steps of GPI-anchor maturation where the unsaturated acyl chain at sn-2 of inositol phosphate is replaced by a saturated stearoyl chain (PubMed:17021251, PubMed:24439110). May catalyze the first step of the fatty acid remodeling, by removing the unsaturated acyl chain at sn-2 of inositol phosphate, generating a lyso-GPI intermediate (Probable). The fatty acid remodeling steps is critical for the integration of GPI-APs into lipid rafts (By similarity)

LOCALIZAÇÃO

Golgi apparatus membrane

MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 4

An autosomal recessive neurologic disorder characterized by profound developmental delay, severe intellectual disability, no speech, psychomotor delay, postnatal microcephaly, and elevated serum alkaline phosphatase.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
66.6 TPM
Skin Sun Exposed Lower leg
41.0 TPM
Glândula salivar
38.3 TPM
Skin Not Sun Exposed Suprapubic
37.4 TPM
Cervix Endocervix
36.0 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 4hyperphosphatasia-intellectual disability syndrome
HGNC:23719UniProt:Q96FM1
KCTD7BTB/POZ domain-containing protein KCTD7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the control of excitability of cortical neurons

LOCALIZAÇÃO

Cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 3, with or without intracellular inclusions

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM3 is an autosomal recessive, severe, form with early onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include intellectual disability, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
27.6 TPM
Útero
24.4 TPM
Cervix Ectocervix
23.9 TPM
Brain Spinal cord cervical c-1
23.6 TPM
Testículo
22.7 TPM
OUTRAS DOENÇAS (1)
progressive myoclonic epilepsy type 3
HGNC:21957UniProt:Q96MP8
ALG9Alpha-1,2-mannosyltransferase ALG9Candidate gene tested inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
ALG9-congenital disorder of glycosylationGillessen-Kaesbach-Nishimura syndromeautosomal dominant polycystic kidney disease
HGNC:15672UniProt:Q9H6U8
STT3BDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3BCandidate gene tested inAltamente restrito
FUNÇÃO

Catalytic subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:39509507). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 com

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1X

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
168.0 TPM
Fibroblastos
124.1 TPM
Testículo
119.3 TPM
Linfócitos
112.5 TPM
Aorta
99.0 TPM
OUTRAS DOENÇAS (1)
STT3B-congenital disorder of glycosylation
HGNC:30611UniProt:Q8TCJ2
STT3ADolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3ADisease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalytic subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:34653363, PubMed:38670073, PubMed:39509507). N-glycosylation occurs cotranslationally and the com

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of CDH1 posttranslational processing and trafficking to plasma membrane
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1W, autosomal recessive

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
135.1 TPM
Linfócitos
70.2 TPM
Cervix Endocervix
65.8 TPM
Ovário
62.2 TPM
Útero
59.5 TPM
OUTRAS DOENÇAS (2)
STT3A-congenital disorder of glycosylationcongenital disorder of glycosylation, type Iw, autosomal dominant
HGNC:6172UniProt:P46977
POFUT1GDP-fucose protein O-fucosyltransferase 1Candidate gene tested inRestrito
FUNÇÃO

Catalyzes the reaction that attaches fucose through an O-glycosidic linkage to a conserved serine or threonine residue found in the consensus sequence C2-X(4,5)-[S/T]-C3 of EGF domains, where C2 and C3 are the second and third conserved cysteines. Specifically uses GDP-fucose as donor substrate and proper disulfide pairing of the substrate EGF domains is required for fucose transfer. Plays a crucial role in NOTCH signaling. Initial fucosylation of NOTCH by POFUT1 generates a substrate for FRINGE

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (1)
Pre-NOTCH Processing in the Endoplasmic Reticulum
MECANISMO DE DOENÇA

Dowling-Degos disease 2

An autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
54.3 TPM
Cervix Endocervix
27.8 TPM
Aorta
27.8 TPM
Ovário
27.2 TPM
Útero
26.9 TPM
OUTRAS DOENÇAS (2)
Dowling-Degos disease 2Dowling-Degos disease
HGNC:14988UniProt:Q9H488
POMT2Protein O-mannosyl-transferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
DSEDermatan-sulfate epimeraseCandidate gene tested inRestrito
FUNÇÃO

Converts D-glucuronic acid to L-iduronic acid (IdoUA) residues. Plays an important role in the biosynthesis of the glycosaminoglycan/mucopolysaccharide dermatan sulfate

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membraneCytoplasmic vesicle membraneMicrosome membrane

VIAS BIOLÓGICAS (1)
DS-GAG biosynthesis
MECANISMO DE DOENÇA

Ehlers-Danlos syndrome, musculocontractural type 2

A form of Ehlers-Danlos syndrome characterized by progressive multisystem manifestations, including joint dislocations and deformities, skin hyperextensibility, skin bruisability and fragility with recurrent large subcutaneous hematomas, cardiac valvular, respiratory, gastrointestinal, and ophthalmologic complications. Motor developmental delay is associated with muscle hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in histology in adulthood.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
45.3 TPM
Nervo tibial
27.5 TPM
Tecido adiposo
25.0 TPM
Adipose Visceral Omentum
22.4 TPM
Linfócitos
19.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
Ehlers-Danlos syndrome, musculocontractural type 2Ehlers-Danlos syndrome, musculocontractural type
HGNC:21144UniProt:Q9UL01
CRPPAD-ribitol-5-phosphate cytidylyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
ALG6Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including t

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1C

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG6-congenital disorder of glycosylation 1C
HGNC:23157UniProt:Q9Y672
FKTNRibitol-5-phosphate transferase FKTNDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligan

LOCALIZAÇÃO

Golgi apparatus membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.9 TPM
Nervo tibial
12.9 TPM
Ovário
12.1 TPM
Útero
10.6 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4autosomal recessive limb-girdle muscular dystrophy type 2Mmuscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4dilated cardiomyopathy 1X
HGNC:3622UniProt:O75072
PIGMGPI alpha-1,4-mannosyltransferase I, catalytic subunitDisease-causing germline mutation(s) inModerado
FUNÇÃO

Catalytic subunit of the glycosylphosphatidylinositol-mannosyltransferase I complex which catalyzes the transfer of the first mannose, via an alpha-1,4 bond from a dolichol-phosphate-mannose (Dol-P-Man) to a 2-acyl-6-alpha-D-glucosaminyl-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (glucosaminyl acyl phosphatidylinositol, GlcN-(acyl)PI) intermediate to generate 2-acyl-6-(alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl)-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Glycosylphosphatidylinositol biosynthesis defect 1

An autosomal recessive disorder characterized by portal vein thrombosis and portal hypertension, absence seizures, macrocephaly, splenomegaly, cytopenias and early-onset cerebral infarctions.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
12.9 TPM
Fibroblastos
11.1 TPM
Testículo
9.3 TPM
Glândula salivar
8.3 TPM
Cervix Endocervix
8.2 TPM
OUTRAS DOENÇAS (1)
hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency
HGNC:18858UniProt:Q9H3S5
COG7Conserved oligomeric Golgi complex subunit 7Candidate gene tested inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2E

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
COG7-congenital disorder of glycosylation
HGNC:18622UniProt:P83436
ALG8Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, includi

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1H

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (3)
polycystic liver disease 3 with or without kidney cystsALG8-congenital disorder of glycosylationautosomal dominant polycystic liver disease
HGNC:23161UniProt:Q9BVK2
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
RIPPLY2Protein ripply2Candidate gene tested inTolerante
FUNÇÃO

Plays a role in somitogenesis. Required for somite segregation and establishment of rostrocaudal polarity in somites (By similarity)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Somitogenesis
MECANISMO DE DOENÇA

Spondylocostal dysostosis 6, autosomal recessive

A form of spondylocostal dysostosis, a condition of variable severity associated with vertebral and rib segmentation defects. The main skeletal malformations include fusion of vertebrae, hemivertebrae, fusion of certain ribs, and other rib malformations. Deformity of the chest and spine (severe scoliosis, kyphoscoliosis and lordosis) is a natural consequence of the malformation and leads to a dwarf-like appearance. As the thorax is small, infants frequently have respiratory insufficiency and repeated respiratory infections resulting in life-threatening complications in the first year of life.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
38.3 TPM
Cerebelo
29.7 TPM
Brain Frontal Cortex BA9
17.6 TPM
Brain Nucleus accumbens basal ganglia
16.2 TPM
Pituitária
12.6 TPM
OUTRAS DOENÇAS (2)
spondylocostal dysostosis 6, autosomal recessiveautosomal recessive spondylocostal dysostosis
HGNC:21390UniProt:Q5TAB7
B3GAT3Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Glycosaminoglycans biosynthesis (PubMed:25893793). Involved in forming the linkage tetrasaccharide present in heparan sulfate and chondroitin sulfate. Transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal-beta-1,3-Gal-beta-1,4-Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans. Can also play a role in the biosynthesis of l2/HNK-1 carbohydrate epitope on glycoproteins

LOCALIZAÇÃO

Golgi apparatus membraneGolgi apparatus, cis-Golgi network

VIAS BIOLÓGICAS (1)
Glycosaminoglycan-protein linkage region biosynthesis
MECANISMO DE DOENÇA

Multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects

An autosomal recessive disease characterized by dysmorphic facies, bilateral dislocations of the elbows, hips, and knees, clubfeet, and short stature, as well as cardiovascular defects.

OUTRAS DOENÇAS (1)
Larsen-like syndrome, B3GAT3 type
HGNC:923UniProt:O94766
KRT5Keratin, type II cytoskeletal 5Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Required for the formation of keratin intermediate filaments in the basal epidermis and maintenance of the skin barrier in response to mechanical stress (By similarity). Regulates the recruitment of Langerhans cells to the epidermis, potentially by modulation of the abundance of macrophage chemotactic cytokines, macrophage inflammatory cytokines and CTNND1 localization in keratinocytes (By similarity)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (7)
Type I hemidesmosome assemblyKeratinizationFormation of the cornified envelopeDevelopmental Lineage of Mammary Stem CellsDevelopmental Lineage of Mammary Gland Luminal Epithelial Cells
MECANISMO DE DOENÇA

Epidermolysis bullosa simplex 2A, generalized severe

A form of epidermolysis bullosa simplex, a group of skin fragility disorders characterized by skin blistering due to cleavage within the basal layer of keratinocytes, and erosions caused by minor mechanical trauma. There is a broad spectrum of clinical severity ranging from minor blistering on the feet, to subtypes with extracutaneous involvement and a lethal outcome. EBS2A is an autosomal dominant, severe form characterized by extensive intraepidermal blistering from the time of birth with herpetiform marginal spreading and central healing. Oral mucosal involvement, nail dystrophy, onychogryposis, formation of milia, and palmoplantar hyperkeratosis are common features.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
7391.8 TPM
Skin Not Sun Exposed Suprapubic
5833.1 TPM
Skin Sun Exposed Lower leg
5020.4 TPM
Vagina
3291.8 TPM
Glândula salivar
340.6 TPM
OUTRAS DOENÇAS (11)
epidermolysis bullosa simplex 2F, with mottled pigmentationepidermolysis bullosa simplex 2B, generalized intermediateepidermolysis bullosa simplex 2E, with migratory circinate erythemaDowling-Degos disease 1
HGNC:6442UniProt:P13647
POMKProtein O-mannose kinaseCandidate gene tested inTolerante
FUNÇÃO

Protein O-mannose kinase that specifically mediates phosphorylation at the 6-position of an O-mannose of the trisaccharide (N-acetylgalactosamine (GalNAc)-beta-1,3-N-acetylglucosamine (GlcNAc)-beta-1,4-mannose) to generate phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-1,3-N-acetylglucosamine-beta-1,4-(phosphate-6-)mannose). Phosphorylated O-mannosyl trisaccharide is a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like d

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
6.4 TPM
Fibroblastos
5.9 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
Cerebelo
2.7 TPM
Testículo
2.3 TPM
OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12limb-girdle muscular dystrophy due to POMK deficiencyobsolete congenital muscular dystrophy with cerebellar involvementmuscular dystrophy-dystroglycanopathy, type A
HGNC:26267UniProt:Q9H5K3
SLC37A4Glucose-6-phosphate exchanger SLC37A4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum. Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction (PubMed:33964207). Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Gluconeogenesis
MECANISMO DE DOENÇA

Glycogen storage disease 1B

A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. Glycogen storage disease type 1B patients also present a tendency towards infections associated with neutropenia, relapsing aphthous gingivostomatitis, and inflammatory bowel disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
77.2 TPM
Intestino delgado
42.5 TPM
Rim - Córtex
34.8 TPM
Pâncreas
34.4 TPM
Nervo tibial
25.9 TPM
OUTRAS DOENÇAS (2)
congenital disorder of glycosylation, type IIwglycogen storage disease Ib
HGNC:4061UniProt:O43826
SEC23BProtein transport protein Sec23BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules for their transport to the Golgi complex

LOCALIZAÇÃO

Cytoplasmic vesicle, COPII-coated vesicle membraneEndoplasmic reticulum membraneCytoplasm, cytosol

MECANISMO DE DOENÇA

Cowden syndrome 7

A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. CWS7 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.2 TPM
Pituitária
53.5 TPM
Testículo
43.3 TPM
Glândula adrenal
42.8 TPM
Glândula salivar
37.9 TPM
OUTRAS DOENÇAS (3)
congenital dyserythropoietic anemia type 2Cowden syndrome 7Cowden disease
HGNC:10702UniProt:Q15437
GMPPBMannose-1-phosphate guanylyltransferase catalytic subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the GMPPA-GMPPB mannose-1-phosphate guanylyltransferase complex (PubMed:33986552). Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids (PubMed:33986552). Can catalyze the reverse reaction in vitro (PubMed:33986552). Together with GMPPA regulates GDP-alpha-D-mannose levels (PubMed:33986552)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.4 TPM
Tireoide
41.5 TPM
Linfócitos
39.6 TPM
Próstata
37.0 TPM
Glândula salivar
32.5 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14autosomal recessive limb-girdle muscular dystrophy type 2Tmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14muscle-eye-brain disease
HGNC:22932UniProt:Q9Y5P6
SLC39A8Metal cation symporter ZIP8Candidate gene tested inRestrito
FUNÇÃO

Electroneutral divalent metal cation:bicarbonate symporter of the plasma membrane mediating the cellular uptake of zinc and manganese, two divalent metal cations important for development, tissue homeostasis and immunity (PubMed:12504855, PubMed:22898811, PubMed:23403290, PubMed:26637978, PubMed:29337306, PubMed:29453449). Transports an electroneutral complex composed of a divalent metal cation and two bicarbonate anions or alternatively a bicarbonate and a selenite anion (PubMed:27166256, PubMe

LOCALIZAÇÃO

Cell membraneLysosome membraneApical cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Zinc influx into cells by the SLC39 gene family
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2N

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
85.8 TPM
Glândula salivar
36.1 TPM
Linfócitos
34.2 TPM
Adipose Visceral Omentum
25.0 TPM
Cervix Endocervix
19.0 TPM
OUTRAS DOENÇAS (1)
SLC39A8-CDG
HGNC:20862UniProt:Q9C0K1
CHSY1Chondroitin sulfate synthase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Involved in the negative control of osteogenesis likely through the modulation of NOTCH signaling

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membraneSecreted

VIAS BIOLÓGICAS (1)
CS-GAG biosynthesis
MECANISMO DE DOENÇA

Temtamy preaxial brachydactyly syndrome

A syndrome characterized by multiple congenital anomalies, intellectual disability, sensorineural deafness, talon cusps of upper central incisors, growth retardation, and bilateral symmetric digital anomalies mainly in the form of preaxial brachydactyly and hyperphalangism.

OUTRAS DOENÇAS (1)
temtamy preaxial brachydactyly syndrome
HGNC:17198UniProt:Q86X52
COG6Conserved oligomeric Golgi complex subunit 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2L

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2L include neonatal intractable focal seizures, vomiting, loss of consciousness, intracranial bleeding due to vitamin K deficiency, and death in infancy.

OUTRAS DOENÇAS (2)
hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndromeCOG6-congenital disorder of glycosylation
HGNC:18621UniProt:Q9Y2V7

Medicamentos e terapias

EPALRESTATPhase 3

Mecanismo: Aldose reductase inhibitor

ACETAZOLAMIDEPhase 2

Mecanismo: Carbonic anhydrase XII inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

280 variantes patogênicas registradas no ClinVar.

🧬 PGM1: NM_002633.3(PGM1):c.1280+1G>C ()
🧬 PGM1: NM_002633.3(PGM1):c.313A>T (p.Lys105Ter) ()
🧬 PGM1: GRCh37/hg19 1p31.3-22.3(chr1:61397219-85940743)x1 ()
🧬 PGM1: NM_002633.3(PGM1):c.1588C>T (p.Gln530Ter) ()
🧬 PGM1: NM_002633.3(PGM1):c.985C>A (p.Arg329Ser) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3,561 variantes classificadas pelo ClinVar.

178
1602
1781
Patogênica (5.0%)
VUS (45.0%)
Benigna (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
ATP6V0A2: NC_000012.12:g.123743783AG[4] [Pathogenic]
DDOST: NM_005216.5(DDOST):c.779C>T (p.Ala260Val) [Uncertain significance]
RPN2: NM_002951.5(RPN2):c.454C>T (p.Leu152Phe) [Uncertain significance]
COG7: NM_153603.4(COG7):c.2270G>T (p.Arg757Leu) [Uncertain significance]
NUS1: NM_138459.5(NUS1):c.737C>T (p.Pro246Leu) [Uncertain significance]

Vias biológicas (Reactome)

110 vias biológicas associadas aos genes desta condição.

Glycogen synthesis Defective PGM1 causes PGM1-CDG Neutrophil degranulation Glycogen breakdown (glycogenolysis) Galactose catabolism GDP-fucose biosynthesis Synthesis of dolichyl-phosphate Maturation of spike protein Reactions specific to the complex N-glycan synthesis pathway Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein Defective MPDU1 causes CDG-1f HS-GAG biosynthesis Defective EXT2 causes exostoses 2 Defective EXT1 causes exostoses 1, TRPS2 and CHDS Defective ALG3 causes CDG-1d Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 DAG1 core M2 glycosylations DAG1 core M1 glycosylations Matriglycan biosynthesis on DAG1 Defective ALG11 causes CDG-1p RHOA GTPase cycle Sialic acid metabolism Defective GNE causes sialuria, NK and IBM2 Glycosaminoglycan-protein linkage region biosynthesis Defective B3GALT6 causes EDSP2 and SEMDJL1 Defective ALG12 causes CDG-1g Pre-NOTCH Processing in Golgi Keratan sulfate biosynthesis Interaction With Cumulus Cells And The Zona Pellucida Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) Defective B4GALT1 causes CDG-2d Lactose synthesis N-Glycan antennae elongation Pre-NOTCH Processing in the Endoplasmic Reticulum COPI-mediated anterograde transport Intra-Golgi traffic Retrograde transport at the Trans-Golgi-Network Dengue Virus-Host Interactions Defective MPI causes MPI-CDG Synthesis of GDP-mannose Defective ALG2 causes CDG-1i Defective ALG14 causes ALG14-CMS Defective DPAGT1 causes CDG-1j, CMSTA2 ER Quality Control Compartment (ERQC) Attachment of GPI anchor to uPAR Defective MOGS causes CDG-2b N-glycan trimming in the ER and Calnexin/Calreticulin cycle Maturation of spike protein Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Synthesis of glycosylphosphatidylinositol (GPI) Defective ALG1 causes CDG-1k Synthesis of dolichyl-phosphate mannose Defective DPM1 causes DPM1-CDG Defective DPM3 causes DPM3-CDG Defective DPM2 causes DPM2-CDG Maturation of DENV proteins Androgen biosynthesis Defective SRD5A3 causes SRD5A3-CDG, KHRZ Defective B3GALTL causes PpS O-glycosylation of TSR domain-containing proteins Defective MGAT2 causes CDG-2a Non-integrin membrane-ECM interactions ECM proteoglycans Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 DAG1 core M3 glycosylations Regulation of expression of SLITs and ROBOs EGR2 and SOX10-mediated initiation of Schwann cell myelination Formation of the dystrophin-glycoprotein complex (DGC) Somitogenesis Apoptosis induced DNA fragmentation Defective PMM2 causes PMM2-CDG Defective MAN1B1 causes MRT15 Nuclear signaling by ERBB4 Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 Amyloid fiber formation TGFBR3 PTM regulation Formation of paraxial mesoderm Formation of the posterior neural plate Neddylation Antigen processing: Ubiquitination & Proteasome degradation Defective ALG9 causes CDG-1l Asparagine N-linked glycosylation Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition PD-L1(CD274) glycosylation and translocation to plasma membrane DS-GAG biosynthesis Defective ALG6 causes CDG-1c Defective ALG8 causes CDG-1h Defective B3GAT3 causes JDSSDHD Type I hemidesmosome assembly Keratinization Formation of the cornified envelope Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells Glycogen storage disease type Ib (SLC37A4) Gluconeogenesis Zinc influx into cells by the SLC39 gene family CS-GAG biosynthesis Defective CHSY1 causes TPBS

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 23
·Pré-clínico10
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 13 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença congênita da glicosilação

Centros de Referência SUS

24 centros habilitados pelo SUS para Doença congênita da glicosilação

Centros para Doença congênita da glicosilação

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

20 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
483 papers (10 anos)
#1

Extensive Hypoglycosylation of Serum N-Glycoproteins in SRD5A3 Deficiency.

Journal of inherited metabolic disease2026 Mar

Polyprenal reductase is an enzyme encoded by the SRD5A3 gene, which is involved in the synthesis of dolichol from polyprenol. Dolichol serves as a carrier for glycan precursors or monosaccharides in N-linked glycosylation. Pathogenic variants in SRD5A3 can result in a congenital disorder of glycosylation (CDG), SRD5A3-CDG, which is inherited in an autosomal recessive manner. Most plasma proteins are glycosylated and changes in the glycosylation of several glycoproteins are associated with pathological consequences. Despite the critical role of SRD5A3 in glycosylation, the impact of its deficiency on the glycosylation of serum proteins remains largely unexplored. In this study, we used tandem mass tag-based multiplexed quantitative approach to analyze serum N-glycoproteomics and proteomics in SRD5A3-CDG patients and controls. We quantified 2200 serum N-glycopeptides from 359 N-glycosites from 204 serum proteins. Extensive hypoglycosylation of serum proteins was observed in patients, with 245 of 291 altered glycopeptides decreased in SRD5A3-CDG. Altered glycopeptides included those derived from haptoglobin, plasma serine protease inhibitor, alpha-1-B glycoprotein, alpha-2-macroglobulin, and ceruloplasmin. Some of these proteins have previously been reported to be associated with liver dysfunction, anemia, and coagulopathy, which could underlie similar clinical features observed in SRD5A3-CDG patients. Overall, our study provides novel insights into alterations in the glycosylation status of specific serum proteins in SRD5A3-CDG. Some of these alterations could be further pursued to develop glycopeptide-based biomarkers as the current diagnosis of SRD5A3-CDG by screening assays remains challenging. In addition, knowledge of altered glycoproteins could enhance our understanding of the disease spectrum and potentially unveil additional therapeutic avenues.

#2

GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.

Journal of inherited metabolic disease2026 Jan

GDP-mannose pyrophosphorylase B (GMPPB) deficiency is a congenital disorder of glycosylation due to pathogenic variants of the GMPPB gene. GMPPB catalyzes GDP-mannose synthesis, an early step in multiple glycosylation pathways, including N-glycosylation, O-mannosylation, C-mannosylation, and glycosylphosphatidylinositol-anchor formation. In fibroblasts (N = 3), myoblasts (N = 4) and in muscle biopsies (N = 4) from a total of 7 GMPPB-deficient patients we found evidence of glycogen accumulation, both in cytosol and in lysosome-like vesicles, presence of heterogeneous storage material, and expansion of the lysosomal compartment. Due to the excess of glycogen in cells and tissues, we investigated acid alpha-glucosidase (GAA) in cultured GMPPB fibroblasts. GAA activity was reduced in GMPPB cells, with an impaired protein maturation and lysosomal localization. Incubation of cells with human recombinant GAA (rhGAA), that is fully glycosylated, showed complete correction of GAA activity, normal processing and lysosomal trafficking, with complete clearance of glycogen storage. These results suggest a secondary impairment of specific lysosomal functions in GMPPB deficiency and add information on the complexity of the pathophysiology of this disorder.

#3

Cerebral blood flow and benzodiazepine receptor distribution in a patient with ALG6-congenital disorder of glycosylation.

Pediatrics international : official journal of the Japan Pediatric Society2026
#4

Unilateral Multicystic Dysplastic Kidney in a Fetus Associated With Parental Genetic and Environmental Risk Factors: A Case Report.

Cureus2026 Jan

Multicystic dysplastic kidney (MCDK) is a congenital renal anomaly identified on prenatal ultrasound. They often arise sporadically and unilaterally. Our case involves an isolated unilateral MCDK in a fetus born to a mother with generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), and gastroesophageal reflux disease (GERD), with the father having chronic occupational lead exposure and a congenital disorder of glycosylation type 1A (PMM2-CDG). Our case highlights the multifactorial etiology of renal dysplasia and its potential role of glycosylation defects and environmental toxicity in abnormal kidney development. Contributions from genetic, environmental, and metabolic influences during nephrogenesis contribute to MCDK.

#5

Neuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins.

Cureus2026 Jan

We report a very rare autosomal recessive metabolic disorder in monozygotic twin sisters caused by the steroid 5a-reductase type 3 (SRD5A3) gene defect, a subtype of congenital disorder of glycosylation (CDG). SRD5A3 activity is required for N-glycosylation of proteins. This step is important for the protein to gain its function. The condition is characterized by severe neurodevelopmental delay, cerebellar atrophy or hypoplasia, ocular abnormalities, and ichthyotic skin changes. We describe 20-month-old female monozygotic twins born to non-consanguineous South Asian parents. Notably, both twins exhibited generalized tonic-clonic seizures starting in early infancy - a feature less commonly reported in SRD5A3-CDG. Physical examination of both children showed central hypotonia and bilateral horizontal nystagmus. Fundoscopy of the twins showed optic disc pallor suggestive of optic atrophy. Other features, such as ichthyosis and joint laxity, were absent. Crucially, despite prominent neurological symptoms, brain MRIs at 20 months were entirely normal, showing no evidence of cerebellar hypoplasia or atrophy typically associated with this condition. Whole-exome sequencing identified a homozygous nonsense mutation at exon 1 c.57G>A (p.Trp19Ter), in the SRD5A3 gene, classified as a pathogenic variant as per the American College of Medical Genetics and Genomics (ACMG), helping in establishing the diagnosis. SRD5A3-CDG should be one of the differentials in infants with unexplained seizures, hypotonia, and early ocular signs. This case highlights the phenotypic diversity of SRD5A3-CDG and demonstrates that structural brain anomalies may be absent in the early years of life. It underscores the importance of considering CDG as a differential in infants with unexplained hypotonia and ocular signs, even in the setting of normal neuroimaging.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC325 artigos no totalmostrando 196

2026

Unilateral Multicystic Dysplastic Kidney in a Fetus Associated With Parental Genetic and Environmental Risk Factors: A Case Report.

Cureus
2026

Neuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins.

Cureus
2026

Specific Detection of Sialyltransferase ST3GAL3 Towards Lipid Acceptors by Liquid Chromatography Coupled with Tandem Mass Spectrometry Indicates Total Loss of Enzyme Activity in ST3GAL3 Pathogenic Variants.

Biomedicines
2026

Extensive Hypoglycosylation of Serum N-Glycoproteins in SRD5A3 Deficiency.

Journal of inherited metabolic disease
2026

PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes.

Journal of translational medicine
2026

A founder variant in Tunisian PMM2-CDG patients: An integrated clinical, radiological, biochemical, and genetic study.

Molecular genetics and metabolism
2026

Early Diagnosis and Targeted Therapy in SLC39A8-Congenital Disorder of Glycosylation: A Case Report From Bulgaria.

Cureus
2026

Clinical, biochemical and genetic characterization of an Egyptian patient with SRD5A3-congenital glycosylation disorder.

Ophthalmic genetics
2026

Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDG.

bioRxiv : the preprint server for biology
2026

Multi-omics analysis reveals ER stress as a main feature in two endothelial cell models of N-linked congenital disorders of glycosylation.

Molecular genetics and metabolism
2026

GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.

Journal of inherited metabolic disease
2026

Cerebral blood flow and benzodiazepine receptor distribution in a patient with ALG6-congenital disorder of glycosylation.

Pediatrics international : official journal of the Japan Pediatric Society
2026

PMM2-CDG and the Role of Liver Transplantation as a Long-Term Solution: A Case Report.

Pediatric transplantation
2026

Disorders of sex development associated with MPI and RSPH1 variants expand the phenotypic spectrum of CDG and PCD in Morocco.

Molecular biology reports
2026

L-fucose supplementation in a patient with global hypofucosylation and a mono-allelic variant in SLC35C1: Clinical improvement and assessment of biomarkers.

Molecular genetics and metabolism
2025

Proposed mechanism for Rft1-mediated scrambling of a dolichol-linked oligosaccharide.

bioRxiv : the preprint server for biology
2025

DDOST-Congenital Disorder of Glycosylation: Defining the Clinical Spectrum and First Report of a Structural Variant.

American journal of medical genetics. Part A
2025

Identification of Compound Heterozygous DPM1 Variants in a Pediatric Patient With Congenital Disorder of Glycosylation Type Ie.

Case reports in pediatrics
2025

Protein losing enteropathy due to congenital disorder of glycosylation: A case report.

SAGE open medical case reports
2025

Novel SSR4 gene splice variant leads to congenital disorder of glycosylation, type Iy.

Frontiers in pediatrics
2025

Congenital disorder of glycosylation type IIb in an infant with developmental and epileptic encephalopathy.

BMJ case reports
2025

Novel PGM1 Mutation in Congenital Disorder of Glycosylation Type 1T: A Case Report of Liver Failure and Myopathy.

The American journal of case reports
2025

Oral D-mannose therapy during pregnancy in a woman with MPI-CDG: A case report and management review.

Molecular genetics and metabolism
2025

Corrigendum to "Incidence and prevalence of phosphomannomutase 2-congenital disorder of glycosylation: Past, present, and future [Molecular Genetics and Metabolism 146 (2025) 109188]".

Molecular genetics and metabolism
2025

Treatment of Single Patient With PMM2-Congenital Disorder of Glycosylation With Govorestat (AT-007), an Aldose Reductase Inhibitor.

JIMD reports
2025

Exploring a Circulating miRNA Signature for PMM2-CDG: Initial Insights Toward Diagnosis, Stratification, and Monitoring.

Journal of inherited metabolic disease
2025

Suspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.

JCEM case reports
2025

Homozygous PGAP2 Mutation Causes Hyperphosphatasia with Mental Retardation Syndrome-3: Genetic and Clinical Evaluation of the Ultra-Rare Inherited Glycosylphosphatidylinositol Biosynthesis Defect.

Molecular syndromology
2025

Immunopathology in PMM2-CDG: Defective glycosylation impact in the TNFα -TNFR1 signalling pathway.

Frontiers in immunology
2025

Defining the clinical spectrum and genotype-phenotype correlations for CCDC115-CDG: A patient report and review of the literature.

Molecular genetics and metabolism
2025

Zscan4 as a Candidate Conveyor of Early Developmental Defects in O-GlcNAc Transferase Intellectual Disability.

Molecular &amp; cellular proteomics : MCP
2026

An OGT Missense Variant With Impaired Enzyme Activity in a Child With Severe Developmental Delay and Hepatoblastoma.

American journal of medical genetics. Part A
2025

Neuromuscular Defects in a Drosophila Model of the Congenital Disorder of Glycosylation SLC35A2-CDG.

Biomolecules
2025

Zebrafish models for congenital disorders of glycosylation (CDG): a systematic review.

Orphanet journal of rare diseases
2025

Congenital Disorder of Glycosylation Following ATP6AP1 Deficiency With Normal Liver Function: A Case Report.

Clinical case reports
2025

Mono-allelic p.R37H Dehydrodolichyl Diphosphate Synthase variants lead to protein glycosylation defects, aberrant lipid profiles and interneuron scarcity in a novel mouse model of progressive epileptic encephalopathy.

bioRxiv : the preprint server for biology
2025

Investigation of the Clinical and Genetic Spectrum of PMM2-CDG: Insights from a Family with a Novel Variant and Previous Studies.

Archives of Iranian medicine
2025

Bi-Allelic Loss-of-Function Variant in MAN1B1 Cause Rafiq Syndrome and Developmental Delay.

International journal of molecular sciences
2026

Activity values of the enzyme phosphomanomutase 2 for diagnosing the CDG Ia glycosylation defect.

Clinica chimica acta; international journal of clinical chemistry
2025

NGLY1-CDDG: report of two cases from India and brief review of literature.

Journal of genetics
2025

Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes.

Frontiers in endocrinology
2025

Incidence and prevalence of phosphomannomutase 2-congenital disorder of glycosylation: Past, present, and future.

Molecular genetics and metabolism
2025

Phenotypic and genotypic description of GMPPA-congenital disorder of glycosylation: A review of 26 cases.

Molecular genetics and metabolism
2025

Persistent Neutropenia and Atopy in an Adolescent: A Subtle Presentation of Phosphoglucomutase 3 Deficiency.

Cureus
2025

A Mild Ataxia-Dominant Phenotype of Phosphomannomutase 2-Congenital Disorder of Glycosylation in a Tunisian Family: Broadening the Geographical Scope.

Journal of movement disorders
2025

PGM1 deficiency disrupts sarcomere and mitochondrial function in a stem-cell cardiomyocyte model.

bioRxiv : the preprint server for biology
2025

Congenital Disorder of Glycosylation in a 40-Year-Old Male with Hypogammaglobulinemia.

Clinical chemistry
2025

Glycosphingolipid synthesis is impaired in SLC35A2-CDG and improves with galactose supplementation.

Cellular and molecular life sciences : CMLS
2025

Case Report: De novo variant of the NUS1 gene associated with developmental delay and autism spectrum disorders in a Chinese family.

Frontiers in pediatrics
2025

A recurrent c.953A>C (p. Gln318Pro) variant in ALG11 causing congenital disorder of glycosylation in Turkish population.

Neurogenetics
2025

Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13.

Cells
2025

Targeted metabolomic evaluation of peripheral blood mononucleated cells from patients with PMM2-CDG.

Scientific reports
2025

The long way to diagnosis: attention disorder, alcohol addiction or congenital disorder of glycosylation? A case report.

BMC psychiatry
2025

Bi-allelic UGGT1 variants cause a congenital disorder of glycosylation.

American journal of human genetics
2025

Diagnostic Utility of Next-Generation Sequencing-based CNV Analysis in Eleven Patients with Peters-Plus Syndrome: A Single-Center Experience.

Journal of clinical research in pediatric endocrinology
2024

Mannose phosphate isomerase-congenital disorder of glycosylation leads to asymptomatic hypoglycemia.

Molecular genetics and metabolism reports
2025

Mannose Phosphate Isomerase Deficiency-Congenital Disorder of Glycosylation (MPI-CDG) Type 1b: Familial Case of Thrombophilia and Liver Disorder.

Clinical chemistry
2025

Beneficial effects of Glc-1,6-P2 modulation on mutant phosphomannomutase-2.

Biochimica et biophysica acta. Molecular cell research
2025

AAV-based gene replacement therapy prevents and halts manifestation of abnormal neurological phenotypes in a novel mouse model of PMM2-CDG.

Gene therapy
2025

The Therapeutic Future for Congenital Disorders of Glycosylation.

Journal of inherited metabolic disease
2025

Recent advances in the clinical spectrum and pathomechanisms associated with X-linked myopathy with excessive autophagy and other VMA21-related disorders.

Journal of neuromuscular diseases
2025

Niemann-Pick C-like Endolysosomal Dysfunction in DHDDS Patient Cells, a Congenital Disorder of Glycosylation, Can Be Treated with Miglustat.

International journal of molecular sciences
2025

Cysteine variants in PMM2 lead to protein instability and higher sensitivity to oxidative stress in PMM2-CDG.

International journal of biological macromolecules
2025

C1GALT1C1-Associated Mosaic Disorder of Glycosylation in a Female.

Journal of inherited metabolic disease
2025

Identification of CNTN2 as a genetic modifier of PIGA-CDG in a family with incomplete penetrance and in Drosophila.

American journal of human genetics
2025

Improvement of Motor Function in SLC39A8-Related Ataxia Through Manganese Supplementation: A Therapeutic Insight.

Movement disorders clinical practice
2025

Rafiq Syndrome: Old Variant in MAN1B1 Gene and Some New Phenotypic Features.

Iranian journal of child neurology
2025

Human genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell.

Life science alliance
2024

Long-chain acyl-CoA synthetase regulates systemic lipid homeostasis via glycosylation-dependent lipoprotein production.

Life metabolism
2025

First case report of effective and safe application of cannabidiol to treat concurrent ALG3-CDG and Lennox-Gastaut Syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Pediatric Anesthetic Management of a Patient With an ALG-13 Gene Mutation, a Rare Congenital Disorder of Glycosylation.

Clinical case reports
2025

Progressive loss of cerebral structures in ALG11-related congenital disorder of glycosylation.

Pediatric neurology
2025

ALG8-CDG: advances in molecular and prenatal phenotyping facilitate prenatal diagnosis and genetic counseling.

QJM : monthly journal of the Association of Physicians
2025

Exploiting O-GlcNAc dyshomeostasis to screen O-GlcNAc transferase intellectual disability variants.

Stem cell reports
2025

Intron retention caused by a canonical splicing variant in SSR4-related congenital disorder of glycosylation.

Journal of human genetics
2025

CHIME Syndrome in a Child With Homozygous PIGL p.Leu167Pro Variant.

American journal of medical genetics. Part A
2024

O-GlcNAcylation modulates expression and abundance of N-glycosylation machinery in an inherited glycosylation disorder.

Cell reports
2024

[Clinical features and genetic analysis of a child with Congenital disorder of glycosylation due to novel variants of COG6 gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

The First Korean Case of MAN1B1-Congenital Disorder of Glycosylation Diagnosed Using Whole-Exome Sequencing and Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry.

Annals of laboratory medicine
2024

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG.

PLoS genetics
2024

Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition.

Molecular genetics and metabolism reports
2025

Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics.

Journal of thrombosis and haemostasis : JTH
2024

N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts.

Glycobiology
2025

Case Report of Friedreich's Ataxia and ALG1 -Related Biochemical Abnormalities in a Patient With Progressive Spastic Paraplegia.

American journal of medical genetics. Part A
2024

Identification of two novel variants in ALG11 causing congenital disorder of glycosylation.

Seizure
2024

Sensitivity of transferrin isoform analysis for PMM2-CDG.

Molecular genetics and metabolism
2024

Identification of CNTN2 as a genetic modifier of PIGA-CDG through pedigree analysis of a family with incomplete penetrance and functional testing in Drosophila.

bioRxiv : the preprint server for biology
2025

Psychiatric assessment and therapy in an adolescent with ALG6-CDG: a six-month follow-up case report.

European child &amp; adolescent psychiatry
2025

Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2-CDG).

Journal of inherited metabolic disease
2024

HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation.

Molecular genetics and metabolism
2024

A novel SSR4 variant associated with congenital disorder of glycosylation: a case report and related analysis.

Frontiers in genetics
2024

O-GlcNAc transferase congenital disorder of glycosylation (OGT-CDG): Potential mechanistic targets revealed by evaluating the OGT interactome.

The Journal of biological chemistry
2024

In vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts.

Molecular genetics and metabolism
2024

Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG.

The Journal of biological chemistry
2024

Insights into molecular and cellular functions of the Golgi calcium/manganese-proton antiporter TMEM165.

The Journal of biological chemistry
2024

Coagulation abnormalities and vascular complications are common in PGM1-CDG.

Molecular genetics and metabolism
2024

Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort.

Molecular genetics and metabolism
2024

HLH and Recurrent EBV Lymphoma as the presenting manifestation of MAGT1 Deficiency: A Systematic Review of the Expanding Disease Spectrum.

Journal of clinical immunology
2024

Genome and RNA sequencing were essential to reveal cryptic intronic variants associated to defective ATP6AP1 mRNA processing.

Molecular genetics and metabolism
2024

Duane syndrome in association with congenital disorder of glycosylation type Ig (ALG12-CDG).

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2024

Mutations in the SLC35C1 gene, contributing to significant differences in fucosylation patterns, may underlie the diverse phenotypic manifestations observed in leukocyte adhesion deficiency type II patients.

The international journal of biochemistry &amp; cell biology
2024

NANS-CDG: Expanding clinical insights with a novel patient with novel variants.

American journal of medical genetics. Part A
2024

A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis.

Cell
2024

SSR4-CDG, an ultra-rare X-linked congenital disorder of glycosylation affecting the TRAP complex: Review of 22 affected individuals including the first adult patient.

Molecular genetics and metabolism
2024

Case report: Novel genotype of ALG2-CDG and confirmation of the heptasaccharide glycan (NeuAc-Gal-GlcNAc-Man2-GlcNAc2) as a specific diagnostic biomarker.

Frontiers in genetics
2024

Neuroectoderm phenotypes in a human stem cell model of O-GlcNAc transferase associated with intellectual disability.

Molecular genetics and metabolism
2024

Destabilization and Degradation of a Disease-Linked PGM1 Protein Variant.

Biochemistry
2024

D-mannose as a new therapy for fucokinase deficiency-related congenital disorder of glycosylation (FCSK-CDG).

Molecular genetics and metabolism
2024

Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.

Molecular genetics and metabolism
2024

Novel insight into FCSK-congenital disorder of glycosylation through a CRISPR-generated cell model.

Molecular genetics &amp; genomic medicine
2024

Expanded prenatal phenotype of ALG12-associated congenital disorder of glycosylation including bilateral multicystic kidneys.

American journal of medical genetics. Part A
2024

ALG13-Congenital Disorder of Glycosylation (ALG13-CDG): Updated clinical and molecular review and clinical management guidelines.

Molecular genetics and metabolism
2024

Transcriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG.

Biochimica et biophysica acta. Molecular basis of disease
2024

Deficient glycan extension and endoplasmic reticulum stresses in ALG3-CDG.

Journal of inherited metabolic disease
2024

A complement C4-derived glycopeptide is a biomarker for PMM2-CDG.

JCI insight
2024

Neurodevelopmental defects in a mouse model of O-GlcNAc transferase intellectual disability.

Disease models &amp; mechanisms
2024

TRAPPC11-CDG muscular dystrophy: Review of 54 cases including a novel patient.

Molecular genetics and metabolism
2025

Phosphomannomutase 2-congenital disorder of glycosylation presenting with very early onset inflammatory bowel disease.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
2024

PIGN c.776T>C (p.Phe259Ser) variant present in trans with a pathogenic variant for PIGN-congenital disorder of glycosylation: Bella-Noah syndrome.

Heliyon
2024

Early onset epileptic and developmental encephalopathy and MOGS variants: a new diagnosis in the whole exome sequencing (WES) ERA : Report of a new patient and review of the literature.

Neurogenetics
2024

Establishment of a human induced pluripotent stem cell line(SDQLCHi059-A)from a patient with congenital disorder of glycosylation carrying heterozygous mutation in MPI gene.

Stem cell research
2024

Metabolic etiologies in children with infantile epileptic spasm syndrome: Experience at a tertiary pediatric neurology center.

Brain &amp; development
2024

Exploring ligand interactions with human phosphomannomutases using recombinant bacterial thermal shift assay and biochemical validation.

Biochimie
2024

Congenital disorder of glycosylation type Ia in a Chinese family: Function analysis of a novel PMM2 complex heterozygosis mutation.

Molecular genetics and metabolism reports
2024

Neural and metabolic dysregulation in PMM2-deficient human in vitro neural models.

Cell reports
2024

Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.

Journal of musculoskeletal &amp; neuronal interactions
2023

Sweet ending: When genetics prevent a dramatic CDG diagnostic mistake.

Clinica chimica acta; international journal of clinical chemistry
2023

Generation of human induced pluripotent stem cell line (AOUMEYi001-A) from a patient affected by Congenital disorders of glycosylation (ALG8-CDG) using self-replicating RNA vector.

Stem cell research
2024

Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis.

Orphanet journal of rare diseases
2023

Untangling adaptive functioning of PMM2-CDG across age and its impact on parental stress: a cross-sectional study.

Scientific reports
2024

Drosophila models of phosphatidylinositol glycan biosynthesis class A congenital disorder of glycosylation (PIGA-CDG) mirror patient phenotypes.

G3 (Bethesda, Md.)
2023

Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu).

Frontiers in genetics
2024

Adult-onset neurodegeneration in XMEN disease.

Journal of neuroimmunology
2023

Congenital Disorder of Glycosylation in a Child with Macrosomia.

Clinical chemistry
2023

Drosophila models of PIGA-CDG mirror patient phenotypes.

bioRxiv : the preprint server for biology
2024

Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.

Genetics in medicine : official journal of the American College of Medical Genetics
2023

Dual effect of tacrolimus on mast cell-mediated allergy and inflammation through Mas-related G protein-coupled receptor X2.

Journal of dermatological science
2023

PIGO-CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations.

JIMD reports
2023

A Case of Congenital Disorder of Glycosylation Type 1b Presenting as Hyperinsulinemic Hypoglycemia and Failure to Thrive.

JCEM case reports
2024

"Hide and seek": Misleading transferrin variants in PMM2-CDG complicate diagnostics.

Proteomics. Clinical applications
2023

Quantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder.

Proceedings of the National Academy of Sciences of the United States of America
2023

Identification of a muscle-specific isoform of VMA21 as a potent actor in X-linked myopathy with excessive autophagy pathogenesis.

Human molecular genetics
2023

Biallelic missense variants in COG3 cause a congenital disorder of glycosylation with impairment of retrograde vesicular trafficking.

Journal of inherited metabolic disease
2023

Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases.

Molecular genetics and metabolism
2023

Interplay of Impaired Cellular Bioenergetics and Autophagy in PMM2-CDG.

Genes
2023

Combined PMM2-CDG and hereditary fructose intolerance in a patient with mild clinical presentation.

Molecular genetics and metabolism
2023

Congenital diaphragmatic hernia in siblings with PIGA-related congenital disorder of glycosylation.

American journal of medical genetics. Part A
2023

An oligogenic case of severe neonatal thrombocytopenia and a purportedly benign variant in GFI1B requiring reinterpretation.

Platelets
2023

Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.

Molecular genetics and metabolism
2023

Inborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.

The Pediatric infectious disease journal
2023

Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2.

The Journal of pharmacy and pharmacology
2023

Activation of ryanodine-sensitive calcium store drives pseudo-allergic dermatitis via Mas-related G protein-coupled receptor X2 in mast cells.

Frontiers in immunology
2023

Metabolic adaptation of human skin fibroblasts to ER stress caused by glycosylation defect in PMM2-CDG.

Molecular genetics and metabolism
2023

Oral sialic acid supplementation in NANS-CDG: Results of a single center, open-label, observational pilot study.

Journal of inherited metabolic disease
2023

An O-GlcNAc transferase pathogenic variant linked to intellectual disability affects pluripotent stem cell self-renewal.

Disease models &amp; mechanisms
2023

D-galactose Supplementation for the Treatment of Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE): A Pilot Trial of Precision Medicine After Epilepsy Surgery.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2023

PMM2 -CDG T237M Mutation in a Patient with Cerebral Palsy-Like Phenotypes Reported from South India.

Global medical genetics
2023

A liposomal carbohydrate vaccine, adjuvanted with an NKT cell agonist, induces rapid and enhanced immune responses and antibody class switching.

Journal of nanobiotechnology
2023

Tracer metabolomics reveals the role of aldose reductase in glycosylation.

Cell reports. Medicine
2023

Novel NUS1 variant in a Chinese patient with progressive myoclonus epilepsy: a case report and systematic review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

Complex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches.

Molecular genetics and metabolism
2023

Substance P analogs devoid of key residues fail to activate human mast cells via MRGPRX2.

Frontiers in immunology
2023

Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.

Molecular genetics and metabolism
2023

MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation.

Journal of thrombosis and haemostasis : JTH
2023

A novel variant in ALG1 gene associated with congenital disorder of glycosylation: A case report and short literature review.

Molecular genetics &amp; genomic medicine
2023

Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.

Therapeutic advances in rare disease
2022

Mannose treatment improves immune deficiency in mannose phosphate isomerase-congenital disorder of glycosylation: case report and review of literature.

Therapeutic advances in rare disease
2022

Congenital disorder of glycosylation - one size does not fit all: a parent's perspective.

Therapeutic advances in rare disease
2023

In Vitro Skeletal Muscle Model of PGM1 Deficiency Reveals Altered Energy Homeostasis.

International journal of molecular sciences
2023

Mannose phosphate isomerase gene mutation leads to a congenital disorder of glycosylation: A rare case report and literature review.

Frontiers in pediatrics
2023

Clinical Presentation of a Patient with a Congenital Disorder of Glycosylation, Type IIs (ATP6AP1), and Liver Transplantation.

International journal of molecular sciences
2023

A Rare Case of Cerebrotendinous Xanthomatosis Associated With a Mutation on COG8 Gene.

Journal of investigative medicine high impact case reports
2023

Abnormal expression of lysosomal glycoproteins in patients with congenital disorders of glycosylation.

BMC research notes
2023

The epilepsy phenotype of ST3GAL3-related developmental and epileptic encephalopathy.

Epilepsia open
2023

The First Congenital Disorders of Glycosylation Patient (Fetus) with Homozygous COG5 c.95T>G Variant.

Molecular syndromology
2023

Liver transplantation recovers hepatic N-glycosylation with persistent IgG glycosylation abnormalities: Three-year follow-up in a patient with phosphomannomutase-2-congenital disorder of glycosylation.

Molecular genetics and metabolism
2023

Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation.

International immunopharmacology
2023

Mirror Movements and Dystonia in SRD5A3-Related Congenital Disorders of Glycosylation: Expanding the Phenotypic and Genotypic Spectrum.

Movement disorders clinical practice
2023

Mast Cell Proteases Cleave Prion Proteins and a Recombinant Ig against PrP Can Activate Human Mast Cells.

Journal of immunology (Baltimore, Md. : 1950)
2023

Long-term outcomes in ALG13-Congenital Disorder of Glycosylation.

American journal of medical genetics. Part A
2023

[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2023

[A case of Congenital disorder of glycosylation due to SSR4 gene deletion].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2023

Phosphomannomutase 2 (PMM2) variants leading to hyperinsulinism-polycystic kidney disease are associated with early-onset inflammatory bowel disease and gastric antral foveolar hyperplasia.

Human genetics
2023

A Case of ALG6-CDG with Explosive Onset of Intractable Epilepsy During Infancy.

Child neurology open
2023

Cysteine Pathogenic Variants of PMM2 Are Sensitive to Environmental Stress with Loss of Structural Stability.

Oxidative medicine and cellular longevity
2022

Phosphomannomutase 2 hyperinsulinemia: Recent advances of genetic pathogenesis, diagnosis, and management.

Frontiers in endocrinology
2023

Rhinovirus infection of the airway epithelium enhances mast cell immune responses via epithelial-derived interferons.

The Journal of allergy and clinical immunology
2023

Mannose: a potential saccharide candidate in disease management.

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
2023

Neurological insights on two siblings with GM3 synthase deficiency due to novel compound heterozygous ST3GAL5 variants.

Brain &amp; development
2023

Fractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic association.

Journal of inherited metabolic disease
2023

Esomeprazole induces structural changes and apoptosis and alters function of in vitro canine neoplastic mast cells.

Veterinary immunology and immunopathology
2022

Case report: The art of anesthesiology-Approaching a minor procedure in a child with MPI-CDG.

Frontiers in pharmacology
2023

Whole exome sequencing reveals several novel variants in congenital disorders of glycosylation and glycogen storage diseases in seven patients from Iran.

Molecular genetics &amp; genomic medicine
2022

A rare case of SRD5A3-CDG in a patient with ataxia and telangiectasia: A case report.

Clinical case reports
2023

Congenital disorder of glycosylation with defective fucosylation 2 (FCSK gene defect): The third report in the literature with a mild phenotype.

Molecular genetics &amp; genomic medicine
2022

Hyperinsulinemic Hypoglycemia Due to PMM2 Mutation in Two Siblings with Autosomal Recessive Polycystic Kidney Disease.

Pediatric reports
Ver todos os 325 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença congênita da glicosilação.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença congênita da glicosilação

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Extensive Hypoglycosylation of Serum N-Glycoproteins in SRD5A3 Deficiency.
    Journal of inherited metabolic disease· 2026· PMID 41732066mais citado
  2. GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.
    Journal of inherited metabolic disease· 2026· PMID 41554119mais citado
  3. Cerebral blood flow and benzodiazepine receptor distribution in a patient with ALG6-congenital disorder of glycosylation.
    Pediatrics international : official journal of the Japan Pediatric Society· 2026· PMID 41542861mais citado
  4. Unilateral Multicystic Dysplastic Kidney in a Fetus Associated With Parental Genetic and Environmental Risk Factors: A Case Report.
    Cureus· 2026· PMID 41769605mais citado
  5. Neuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins.
    Cureus· 2026· PMID 41769439mais citado
  6. Immunological Manifestations in GALE Deficiency: Extending the Spectrum Beyond Thrombocytopenia and Galactosemia.
    J Clin Immunol· 2026· PMID 41986803recente
  7. Lipo-Glc-1,6-P(2): A Bioprecursor Prodrug for Phosphomannomutase-2 Congenital Disorder of Glycosylation.
    IUBMB Life· 2026· PMID 41968365recente
  8. Early neonatal diagnosis of SSR4-related congenital disorder of glycosylation with severe congenital heart defects: a case report and systematic review.
    Front Pediatr· 2026· PMID 41960028recente
  9. A Homozygous Nonsense Variant in the Oligosaccharyltransferase Complex Gene, RPN1, Causes a Congenital Disorder of Glycosylation.
    HGG Adv· 2026· PMID 41935956recente
  10. Expanded Clinical Spectrum of Autosomal-Dominant STT3A-CDG.
    Biomolecules· 2026· PMID 41897354recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:137(Orphanet)
  2. MONDO:0015286(MONDO)
  3. GARD:10307(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1125675(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doença congênita da glicosilação

ORPHA:137 · MONDO:0015286
Prevalência
Unknown
Herança
Autosomal recessive, X-linked recessive
CID-10
E77.8 · Outros distúrbios do metabolismo de glicoproteínas
Ensaios
5 ativos
Medicamentos
2 registrados
Início
Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0282577
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades